“showed a trend”

The decrease of each cell type alone was not significantly associated with any clinical trait, but showed a trend for association with disease severity (Fig. 2 B–D, F –H; p < 0.13 (CD3 + CD4 + ), p < 0.09 (CD3 + CD8 + )).

Groups E and ME showed a trend towards increased cardiomyocyte area when compared with group S ( p = 0.13 and p = 0.19, respectively).

Comparing scans after treatment with escitalopram (n = 8) to placebo (n = 8) showed a trend ( p = 0.13) towards lower extrastriatal SERT BPND in the SSRI group (median SERT occupancy of 64.6%).

Further, both the stroke groups showed a trend of shorter compensatory steps than healthy older adults ( p = 0.13).

For the serum fructose level, there were no significant differences between the four groups, and the 20% FRU group showed a trend of higher levels when compared with the CON ( p = 0.13) and 10% GLU ( p = 0.28) groups.

The results also showed a trend that upgraded patients were older (p = 0.130), with more positive cores (p = 0.608), maximum percentage of cancer in a given core (0.071), and smaller prostates (p = 0.806), but none of these variables were statistically significant.

Picolinic acid addition showed a trend (p = 0.13) toward increased lifespan.

The quarterly analysis showed a trend for more cases to have onset from July to September and fewer cases from January to March (goodness-of-fit χ 2 = 5.63, p = 0.13).

−34.2 ± 8.6 %, p = 0.21) was not significant but showed a trend for improvement (60 ± 11 vs. 64 ± 8 %, p = 0.13).

Survival curves showed a trend towards improved survival (assessed by number of mice with tumor volume <500 mm 3 ) in mice treated with CX-4945 alone compared to controls ( P = .13) ( Figure 5 B ).

Interestingly, spines with PSs spinules showed a trend toward higher rates of perforated PSDs versus spines projecting AdjS spinules (24.1% vs. 10.0%, p = 0.13, n = 58 and 48, for PSs vs.

Additionally, the number of EV particles produced by non-irradiated control SFs and irradiated SF showed a trend (7.7x±3.6 × 10 9 vs. 12.4 ± 6.9 × 10 9 ; p = 0.13) of increased EV particles per cell in irradiated SFs, however this was not statistically significant ( Figure 1G ).

A concentration of 50 μM showed a trend towards increased LDH release, although the difference to untreated control cells remained statistically non-significant ( p = 0.13).

Excluding the 8 infants who were studied at both time points, HEU infants showed a trend toward higher NK cell proportions at 6 months compared to birth (increase from median of 1.85% at birth to 3.12% at 6 months; p = 0.13), whereas HUU infants had lower NK cell proportions at 6 months compared to birth (decrease from 9.4% at birth to 4.65% at 6 months; p < 0.0001).

At this time-point, levels of IL-18 and ICAM-1 in the post-DAAs HIV/HCV group were comparable to those observed in the HIV group and in HC donors, whereas VCAM-1 levels remained significantly increased in the post-DAAs HIV/HCV group compared to HC donors ( p = 0.006 for the global comparison and p = 0.001 for the pair-wise comparison between the post-DAAs HIV/HCV group and HC donors), and levels of IP-10 showed a trend ( p = 0.13 for the global comparison and p = 0.07 for the pair-wise comparison between the post-DAAs HIV/VCV group and HC donors) ( Figure 3 ).

The pooled result showed a trend toward INV angle increase (SMD = 0.86; 95% CI: −0.24 to 1.95; P = 0.13), but without statistical significance.

controls, although MCI/MI showed a trend of increasing values for all three proteases (each p = 0.13).

In this disease setting TG4010 showed a trend to benefit PFS at 6 months with rates of 44% for vaccinated versus 35% for controls (p= 0.13) and in terms of trends for benefit patient’s overall survival Stimuvax show a HR 0.74 with p = 0.112, Lucanix achieve a clinical response of 15% and better survival in the high-dose group, Racotumumab achieve numerical differences of 9.93 months for Vaccinated group vs. 4.53 months for Control group and CIMAvax EGF achieve 3.5 month of benefit for the subset of 60 years old and younger patients (Table 2 ).

Results showed a trend in favor of HIG treatment, but the difference between the two groups was not statistically significant (30 vs. 44%; p = 0.13).

Blood CD4 + T cell levels showed a trend toward CD4 restoration ( r = 0.24; P = 0.13) with only a 1.3-fold reduction ( P = 0.2) in participants receiving ART for more than 10 years ( Figure 4D ), and this is consistent with a 1.1 reduction in absolute CD4 + T cell counts (HIV – versus HIV + VL < 20 ART > 10 years, median 858 versus 795 cells/mm 3 , P = 0.99).

Patients with no detectable ctDNA at any time point postoperatively showed a trend toward improved RFS (RFS = 85%) compared with those with detectable ctDNA (58%), with an HR of 0.34 (95% CI, 0.13–0.92; P = 0.130).

The pooled results showed a trend favoring the HA group, but did not show any differences (MD 6.01; 95%CI −1.74 to 13.75; P = 0.13).

Patients <55 also showed a trend towards an increased risk of death with a HR of 1.49 (p=0.13).

From bulk RNA-seq of PDAC samples, TRIM22 showed a trend of being upregulated ( P = 0.13 ), whereas HIST1H3B was significantly downregulated ( P = 0.0009 ) in ulixertinib-treated cohorts (Supplementary Fig.

Interestingly, whereas the forelimb impact impulses showed a trend for negative allometry (M b 0.99±0.11 , p = 0.13; M b 1.05±0.22 , p = 0.59, walk and slow run respectively), the hind limb impact impulses showed a trend for positive allometry (M b 1.38±0.14 , p = 0.15; M b 1.21±0.22 , p = 0.86 walk and slow run respectively).